February 15, 2016
Astellas Pharma has completed the acquisition of Ocata Therapeutics, a Massachusetts-based biotechnology firm specializing in cell therapies for ophthalmology, for some US$384 million, obtaining a controlling stake in the company. The Japanese company announced the acquisition in November and launched...read more